In:
Cancer, Wiley, Vol. 125, No. 22 ( 2019-11-15), p. 4033-4042
Abstract:
Conditional on surviving for 2 years after bone marrow transplant (BMT), 10‐year overall survival is comparable for patients with chronic myelogenous leukemia (CML) who undergo transplant with and without pre‐BMT tyrosine kinase inhibitors (TKI). Non–CML‐related causes are the primary causes of death among patients with CML who survive for ≥2 years from BMT, irrespective of pre‐BMT TKI exposure.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
DOI:
10.1002/cncr.v125.22
Language:
English
Publisher:
Wiley
Publication Date:
2019
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
1429-1